Literature DB >> 10898344

Prostate carcinoma: production of bioactive factors.

L J Deftos1.   

Abstract

BACKGROUND: Many molecular mechanisms regulate prostate carcinoma pathogenesis, proliferation, and progression to bone metastases. The basic molecular mechanisms are endocrine, paracrine, autocrine, and intracrine. These mechanisms can be mediated by a variety of agents, including gonadal and adrenal steroids, retinoic acid and vitamin D derivatives, neuroendocrine factors, growth factors, cytokines, lymphokine, and bone factors. Prominent among them is parathyroid hormone-related protein (PTHrP).
METHODS: The author studied the expression and regulation of PTHrP production in prostate carcinoma cells with nucleic acid and immunochemical probes for the polypeptide. The robust expression of this oncoprotein by prostate carcinoma has been demonstrated. In the current study the author reviews his results and the studies of other investigators regarding PTHrP and the variety of bioactive factors produced by prostate cells.
RESULTS: PTHrP is expressed by most prostate carcinoma. It also is expressed by normal and hyperplastic prostate cells, and there is a gradient of expression that peaks in malignant prostate cells. PTHrP is processed by carcinoma cells into peptides that have unique biologic effects. Among them are regulation of growth and cytokine expression. It has been observed that the effect of PTHrP can be mediated by novel intracrine pathways in prostate carcinoma. These mechanisms influence transduction of growth regulatory signaling pathways, cell proliferation, immunoregulation, and angiogenesis.
CONCLUSIONS: The current study identified PTHrP among the bioactive prostate factors that appear to participate in prostate carcinoma pathogenesis and progression. This oncofetal protein is commonly expressed by prostate carcinoma, and its regulatory interactions with other bioactive prostate cell products play an important role in the pathobiology of prostate carcinoma. Understanding these regulatory interactions among prostate carcinoma, its cell products, and the skeleton continues to provide insights into the pathogenesis of this disease entity and may provide clues to clinical management.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10898344     DOI: 10.1002/1097-0142(20000615)88:12+<3002::aid-cncr16>3.3.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini.

Authors:  Eva Gonzalez-Suarez; Daniel Branstetter; Allison Armstrong; Huyen Dinh; Hal Blumberg; William C Dougall
Journal:  Mol Cell Biol       Date:  2006-12-04       Impact factor: 4.272

2.  1,25-Dihydroxyvitamin D(3) regulates PTHrP expression via transcriptional, post-transcriptional and post-translational pathways.

Authors:  Vandanajay Bhatia; Ramanjaneya V Mula; Miriam Falzon
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

Review 3.  Extracellular Vesicle-Mediated Bone Remodeling and Bone Metastasis: Implications in Prostate Cancer.

Authors:  Kalyani C Patil; Carolina Soekmadji
Journal:  Subcell Biochem       Date:  2021

Review 4.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

5.  PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3).

Authors:  Xiaoli Shen; Ramanjaneya V R Mula; Jing Li; Nancy L Weigel; Miriam Falzon
Journal:  Steroids       Date:  2007-08-15       Impact factor: 2.668

6.  EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.

Authors:  Vandanajay Bhatia; Manjit K Saini; Xiaoli Shen; Lian X Bi; Suimin Qiu; Nancy L Weigel; Miriam Falzon
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

7.  Parathyroid hormone related-protein promotes epithelial-to-mesenchymal transition in prostate cancer.

Authors:  Weg M Ongkeko; Doug Burton; Alan Kiang; Eric Abhold; Selena Z Kuo; Elham Rahimy; Meng Yang; Robert M Hoffman; Jessica Wang-Rodriguez; Leonard J Deftos
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.